Telmisartan to reduce insulin resistance in HIV-positive individuals on combination antiretroviral therapy: the TAILoR dose-ranging Phase II RCT (2019)

First Author: Pushpakom S
Attributed to:  Renewal of the Network of Hubs for Trials Methodology Research. funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.3310/eme06060

PubMed Identifier: 31318501

Publication URI: http://europepmc.org/abstract/MED/31318501

Type: Journal Article/Review

Parent Publication: Efficacy and Mechanism Evaluation

Issue: 6